-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1105 Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
Program: Oral and Poster Abstracts
Type: Oral
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Emerging Immunotherapy Approaches in Hodgkin Lymphoma
Monday, December 5, 2016: 4:30 PM
Room 6B (San Diego Convention Center)

Alex F Herrera, MD1, Nancy L Bartlett, MD2, Radhakrishnan Ramchandren, MD3*, Julie M Vose, MD4, Alison J Moskowitz, MD5, Tatyana A Feldman, MD6, Ann S LaCasce, MD7, Stephen M Ansell, MD, PhD8*, Craig H. Moskowitz, MD5, Keenan Fenton9*, Kazunobu Kato, MD10, Abraham Fong, MD, PhD9 and Ranjana H Advani, MD11

1Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
2Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO
3Karmanos Cancer Institute, Detroit, MI
4Department of Hematology Oncology, University of Nebraska Medical Center, Omaha, NE
5Memorial Sloan-Kettering Cancer Center, New York, NY
6John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
7Dana-Farber Cancer Institute, Boston, MA
8Mayo Clinic, Rochester, MN
9Seattle Genetics, Inc., Bothell, WA
10Bristol-Myers Squibb, Princeton, NJ
11Stanford University Medical Center, Palo Alto, CA


Brentuximab vedotin (BV) is an antibody-drug conjugate directed against CD30, a receptor that engages the CD30 ligand expressed on immune cells in the tumor microenvironment, promoting tumor cell growth (Montanari 2014, Hansen 2014).  Through disruption of the microtubule network, BV induces apoptotic cell death, and may initiate an antitumor immune response (i.e., immunogenic cell death) through the induction of endoplasmic reticulum (ER) stress (Gardai 2015).  Nivolumab is a fully human monoclonal PD-1 blocking antibody that prevents tumor immune evasion.  Both agents have independent high single-agent response rates in patients (pts) with relapsed or refractory (R/R) Hodgkin lymphoma (HL), and when used in combination, may exhibit mechanistic synergy.  Given the demonstrated efficacy of both BV and nivolumab, together these agents could yield improved CR rates prior to ASCT in pts with R/R HL, and potentially better long-term outcomes.


A phase 1/2 study is ongoing to evaluate the safety and antitumor activity of BV administered in combination with nivolumab as first salvage therapy in pts with R/R classical HL after standard frontline chemotherapy (NCT02572167).  Adult pts are treated in 21-day cycles for up to 4 cycles (12 weeks).  Pts receive 1.8 mg/kg BV on Cycle 1 Day 1, and 3 mg/kg nivolumab on Cycle 1 Day 8.  For cycles 2 through 4, BV and nivolumab are administered on Day 1 of each cycle at the same doses.  After completion of the Cycle 4 response assessment, pts are eligible to undergo ASCT.  Investigator assessment of lymphoma response and progression is per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014).


Twenty-five pts (60% female) with a median age of 32 years (range, 18-69) have been enrolled to date.  Sixty percent of pts have relapsed disease, 36% have primary refractory disease (failure to achieve CR with frontline therapy, or relapse within 3 months of completing frontline therapy), and 1 pt (4%) has unknown status.  At the time of enrollment, 32% of pts presented with extranodal disease and 16% with bulky disease. 

At the time of the data extract, 23 pts had received treatment.  An increased incidence of infusion-related reactions (IRRs) was observed at the start of combination treatment in Cycle 2 during the BV infusion leading to 1 dose delay.  Premedication with corticosteroids (hydrocortisone 100 mg or equivalent) and antihistamines at Cycles 2-4 was instituted through a protocol amendment.  

Six pts have completed combination treatment, and all have achieved an objective response (ORR, 100%), with 3 of 6 achieving a complete metabolic response (CmR, 50%).  All 6 pts have proceeded directly to ASCT.  Median number of CD34+ cells collected was 12.9 x106 cells/kg (range, 5-26) in a mean number of 1.7 apheresis sessions (range, 1-2).

Adverse events (AEs) for all pts are summarized prior to ASCT.  Eighteen of the 23 treated pts (78%) experienced adverse events (AEs).  Fifteen pts (65%) had AEs ≤ Grade 2 in severity and 3 pts (13%) experienced Grade 3 AEs.  No pts experienced Grade 4 AEs pre-ASCT.  Fatigue was the most common AE occurring in 35% of pts, followed by nausea (26%), rash (22%), dyspnea, myalgia, and pruritus (17% each).  One pt experienced a treatment-related serious adverse event (SAE) of dehydration, hypercalcemia, and acute kidney injury.  Immune-related adverse events (IrAEs) were experienced by 3 pts; 2 pts who experienced Grade 1 rash treated with topical steroids, and 1 pt who experienced Grade 1 hypothyroidism.  No pts have discontinued treatment prematurely.

In addition to Reed-Sternberg cells, CD30 is expressed on activated T cells.  Preliminary biomarker data indicate a BV-induced decrease in the percentage of CD4+ T regulatory (Treg) cells at C1D8, with no decrease in proliferating CD8+ T cells, and no significant decrease observed in the percentage of CD4+ Th1 cells compared to baseline for 5 of 6 pts (83%).  Nivolumab induced a robust expansion of T cells at C1D15. 


Early data suggest the combination of BV and nivolumab is an active and well-tolerated salvage therapy in pts with R/R HL.  While an elevated incidence of IRRs has been observed, toxicities with this regimen appear to be tolerable overall.  The preliminary antitumor activity suggests this combination may be a promising option for R/R HL pts.  Updated results will be shared at the time of presentation. 

Disclosures: Herrera: Pharmacyclics: Research Funding; Merck: Research Funding; Immune Design: Research Funding; Genentech: Research Funding; Adaptive Biotechnologies: Research Funding; Seattle Genetics: Research Funding. Bartlett: Gilead: Consultancy. Moskowitz: BMS: Honoraria, Research Funding; Seattle Genetics: Honoraria, Research Funding. Feldman: Abbvie/Pharmacyclics/Janssen: Speakers Bureau; Seattle Genetics: Consultancy, Research Funding, Speakers Bureau; Celgene: Consultancy, Speakers Bureau. LaCasce: Seattle Genetics: Research Funding; Forty Seven Inc.: Consultancy. Ansell: Bristol Myers Squibb: Research Funding; Seattle Genetics: Research Funding; Celldex: Research Funding; Affimed: Research Funding. Fenton: Seattle Genetics: Employment, Equity Ownership. Kato: Bristol-Myers Squibb: Employment. Fong: Seattle Genetics: Employment, Equity Ownership.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH